<?xml version="1.0" encoding="UTF-8"?>
<p id="para110">The PERCH case-control study design has been previously described.
 <xref rid="bib4" ref-type="bibr">4</xref>, 
 <xref rid="bib10" ref-type="bibr">10</xref>, 
 <xref rid="bib11" ref-type="bibr">11</xref> Briefly, we assessed the causes of WHO-defined
 <xref rid="bib12" ref-type="bibr">
  <sup>12</sup>
 </xref> severe or very severe pneumonia (pre-2013 definitions, originally presented in 2005) among children aged 1â€“59 months presented and admitted to a hospital with this condition. The nine study locations in seven countries (Basse, The Gambia; Bamako, Mali; Lusaka, Zambia; Soweto, South Africa; Kilifi, Kenya; Dhaka and Matlab, Bangladesh; and Nakhon Phanom and Sa Kaeo, Thailand) were selected to represent diverse epidemiological conditions through an open call for applications.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> Site characteristics, vaccination schedules for each country, and screening and enrolment procedures are described in the 
 <xref rid="sec1" ref-type="sec">appendix</xref>.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> All sites, except those in Thailand, were routinely using Hib vaccine; pneumococcal conjugate vaccine (PCV) was in routine use in The Gambia, Kenya, Mali, and South Africa and was in routine use in Zambia for the last few months of the PERCH study. Influenza vaccine was not in routine use at any site.
</p>
